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esponsibility of InstAbstract Shenfu Injection (SFI) is a well-deﬁned Chinese herbal formulation that is obtained from red
ginseng and processed aconite root. The main active constituents in SFI are ginsenosides and aconitum
alkaloids. In this work, ginsenosides (ginsenoside Rg1, ginsenoside Rb1 and ginsenoside Rc) and
aconitum alkaloids (benzoylmesaconine and fuziline) were used as the index components to explore the
pharmacokinetic behavior of SFI. A selective and sensitive HPLC–MS/MS method was developed for the
quantiﬁcation of ginsenosides and aconitum alkaloids in dog plasma and was used to characterize the
pharmacokinetics of the ﬁve index components after intravenous drip of three different dosages of SFI in
beagle dogs. The pharmacokinetic properties of the index components were linear over the dose range of
2–8 mL/kg.
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Shenfu injection pharmacokinetics in dogs 5851. Introduction
Shenfu Injection (SFI) is a commonly used traditional Chinese
medicine (TCM) composed of the extracts of red ginseng (steamed
roots of Panax ginseng) and aconite (processed lateral roots of
Aconitum carmichaeli). SFI has been widely accepted as an
effective therapeutic approach in clinic for its protective effects
on ischemia/reperfusion injury and therapeutic effects on shock,
acute myocardial infarction, chronic congestive heart failure and
ischemic cardiomyopathy with heart insufﬁciency1–7. It can be
used alone or integrated with other routine treatments.
SFI dosing used in clinical practice ranges from 20 mL to 200 mL,
and occasionally higher. The curative effect of SFI depends on its
dose8–10. It is necessary to investigate the pharmacokinetics of the SFI
index components to deﬁne the relationship between dose and drug
exposure. As a typical multiple-constituent Chinese herbal formulation,
SFI contains multiple active ingredients, including ginsenosides and
aconitum alkaloids. Ginsenosides are divided into 20(S)-protopanaxa-
triol (Ppt) and 20(S)-protopanaxadiol (Ppd) types based on their
aglycone moieties. The half-life (t1/2β) of Ppd ginsenoside (Rb1 and
Rc) is longer than that of Ppt ginsenoside (Rg1), and Rg1 showed fast
elimination in vivo with a short t1/2β of 0.45 h, while Rb1 and Rc had
long t1/2β values of 58 h and 20 h, respectively
11–13. Aconitum
alkaloids are composed of diester-, monoester- and amine-diterpenoid
alkaloids, with aconitine (CA), benzoylmesaconine (BMA) and fuziline
(FN) the typical components of the three types of alkaloids,
respectively. With proper processing the highly toxic diester-
diterpenoid alkaloids can be easily hydrolyzed and converted to
monoester-diterpenoid alkaloids, whose toxicity is 50- to 500-fold
lower than that of diester-diterpenoid alkaloids14,15. Monitoring their
plasma concentrations after administration is still of importance for
safety and efﬁcacy evaluation in clinical pharmacotherapy. A number
of studies have evaluated the pharmacokinetic parameters of these
components with different preparations16–20; however, only a few
studies have evaluated the pharmacokinetics of “Shenfu”: Li et al.21
revealed the pharmacokinetic proﬁles of seven ginsenosides in rat
plasma in a single dose study and Zhang et al.22 carried out a
pharmacokinetic study of six aconitum alkaloids in a phase I clinical
trial, but only the ester-alkaloids were chosen as the index components
without data on the amine-diterpenoid alkaloids. We propose that the
pharmacokinetic behavior of multiple ingredients in a single herb
would more accurately portray the pharmacokinetics of the entire
medicinal compound in vivo. Moreover, comparison of pharmacoki-
netic proﬁles after various doses will be helpful for the rational use of
this multiple-constituent TCM. We selected Rg1, Rb1, Rc, BMA and
FN as the index components of SFI to gain a more comprehensive
understanding of the pharmacokinetic behavior of SFI.
Towards this goal, a simple, sensitive yet reliable analytical
method to determine BMA, FN, Rg1, Rb1 and Rc in plasma is
important for illustrating the pharmacokinetic behavior of SFI.
Various methods have been developed for the detection of
ginsenosides and aconitum alkaloids16–18,23,24, but it is still
challenge to achieve simultaneous determination of both ginseno-
sides and aconitum alkaloids in biological samples because of their
very different physicochemical properties and polarities25. Owing
to its excellent selectivity and sensitivity, liquid chromatography
coupled to tandem mass spectrum (LC–MS/MS) is becoming a
useful technique for determination of these components in
pharmaceutical and biological samples, with the ability to dis-
criminate the different components based on their distinct mole-
cular weights. In this work, a rapid and sensitive HPLC–MS/MS
method was established for quantiﬁcation of ginsenosides (Rg1,Rb1 and Rc) and aconitum alkaloids (BMA and FN) in plasma
with different sample preparations. We applied the method to
determine the pharmacokinetics of SFI in beagles after intravenous
drip infusion injection of a single dose with ascending doses of 2,
4 and 8 mL/kg.2. Materials and methods
2.1. Materials
The reference standards of BMA, FN, Rc (purity 498%) were
purchased from Chengdu Pufei De Biotech Co., Ltd. (Chengdu,
China). Rg1 and Rb1 (purity 493%), lappaconite hydrobromide
(LA) and diazepam (DZP) were purchased from National Institute
for the Control of Pharmaceutical and Biological Products (Beij-
ing, China). Methanol of HPLC grade was purchased from Merck
(Darmstadt, Germany). Acetic acid of HPLC-LA grade was
purchased from ROE (Newark, New Castle, DE, USA). Doubly
deionized water was puriﬁed using a Millipore Simplicity System
(Millipore, Bedford, MA, USA). Other reagents of analytical grade
were obtained from Sinopharm Chemical Reagent Co., Ltd.
(Shanghai, China). Shenfu Injection was supplied by a Chinese
pharmaceutical company (San-Jiu Pharmaceutical Company of
Ya’an, China).2.2. HPLC–MS/MS instruments and conditions
An API 3000 Qtrap triple quadrupole mass spectrometer with
electrospray ionization (ESI) (Applied Biosystem/MDS SCIEX,
Foster City, CA, USA) was used to determine concentrations of
aconitum alkaloids and ginsenosides in blood. The main working
parameters for mass spectrometry were set as follows: nebulizer gas,
12; curtain gas, 8; collision gas, 4; gas 2, 7500; ion source
temperature, 500 1C; ion spray voltage: 5000 V. LA and DZP were
used as the internal standards (IS) for quantiﬁcation of aconite
alkaloids and ginsenosides in plasma, respectively. The quantiﬁcation
was performed using multiple-reaction monitoring (MRM) in the
positive-ion mode. The compound-dependent MS/MS parameters for
analytes in the MRM mode are summarized in Table 1. HPLC
conditions: column, Waters Atlantis T3 column (100 mm 2.1 mm,
5 μm); column temperature, 30 1C; injection volume, 10 μL. The
analysis was performed at a ﬂow rate of 0.25 mL/min, and the mobile
phase consisted of 0.1% formic acid: methanol (40:60, v/v).2.3. Preparation of stock and working standard solutions
Stock solutions of BMA and FN were prepared in acetonitrile at a
concentration of 400 μg/mL and ginsenoside Rg1, ginsenoside Rb1,
ginsenoside Rc, DZP (IS for ginsenosides) and LA (IS for aconitum
alkaloids) were prepared in methanol at a concentration of
400 μg/mL. All solutions were stored at 4 1C until analysis. The
working solutions for aconitum alkaloids were prepared in metha-
nol–water (1:1, v/v) at concentrations of 1000, 400, 200, 100, 40,
20, 10 and 4 ng/mL. The working solutions for ginsenosides were
prepared in methanol–water (1:1, v/v) at different concentrations
(the concentrations of Rg1 were 4, 2, 1, 0.4, 0.2, 0.1, 0.05,
0.02 μg/mL, Rb1 were 20, 10, 5, 2, 1, 0.5, 0.25, 0.1 μg/mL, and
Rc were 10, 5, 2.5, 1, 0.5, 0.25, 0.125, 0.05 μg/mL).
Table 1 Optimized MS/MS parameters of analytes and internal standards in MRM mode.
Compound Q1/Q3 DP (V) FP (V) EP (V) CE (V) CXP (V)
Rb1 1131.7/365.1 200 242 11 81 19
Rg1 823.6/643.4 78 304 9 51 14
Rc 1101.6/335.2 189 244 12 75 17
BMA 590.3/105.1 109 287 11 71 16
FN 454.2/436.4 109 224 13 48 51
LA 585.4/162.2 42 221 13 62 14
DZP 285.0/193.2 82 295 8 48 8
DP: declustering potential; EP: entrance potential; FP: focusing potential; CE: collision energy; CXP: cell exit potential.
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Since ginsenosides and aconitum alkaloids have different physi-
cochemical properties and are present at different concentrations in
plasma samples, two sample preparation procedures were
employed in this work for their determination.2.4.1. Sample preparation for the determination of alkaloids
To a 400 μL aliquot of plasma 40 μL of IS (LA, 100 ng/mL) and
40 μL of 50% methanol were added in a 4 mL EP tube. After
vortex-mixing for 30 s the mixture was alkalinized with 40 μL of
ammonium hydroxide and extracted with 2 mL of ethylacetate.
After vortexing the resulting mixture was centrifuged at 4000 rpm
(YINGTAI TD4A, China) for 5 min. One mL of supernatant was
transferred into a 2 mL centrifuge tube and evaporated to dryness
under a stream of nitrogen at 40 1C. The residue was reconstituted
in 100 μL of mobile phase. An aliquot of 10 μL of the ﬁnal testing
sample was injected into LCMS/MS system for analysis.2.4.2. Sample preparation for the determination of ginsenosides
Aliquots (20 μL) of plasma were diluted with 180 μL water and
spiked with 20 μL of IS, mixed by vortexing for 30 s, and extracted
with 1 mL of ethyl acetate–isopropanol (1:1, v/v) by vortex-mixing
for 3 min. After centrifugation at 13,000 rpm at 4 1C for 10 min, the
organic phase was quantitatively transferred to a clean centrifuge
tube and evaporated to dryness under a gentle stream of nitrogen at
40 1C. The residue was reconstituted with 200 μL of mobile phase
and vortex-mixed for 3 min, and then centrifuged at 13,000 rpm
(YINGTAI TGL16M, China) for 10 min. An aliquot of 10 μL of the
ﬁnal testing sample was injected into LCMS/MS system for
analysis.
Quality control (QC) samples for the validation were prepared
daily by adding an appropriate volume of standard working
solutions into the blank plasma and processed the same way as
described above to obtain three different concentration levels
(alkaloids-low, -medium and -high at 0.5, 5 and 40 ng/mL and
ginsenosides-low, -medium and -high at 0.05/0.25/0.125, 0.4/2/1
and 3/15/7.5 μg/mL for Rg1/Rb1/Rc, respectively).2.5. Method validation
2.5.1. Speciﬁcity and selectivity
The endogenous interference from a biological sample was assessed
by comparing chromatograms of blank dog blood, blood spiked
with BMA, FN, LA or Rg1, Rb1, Rc, DZP and plasma samples
obtained after intravenous drip infusion of SFI to beagle dogs.2.5.2. Linearity of calibration curve and LLOQ
The linearity was investigated by preparing calibration curves with
blood spiked with standards at different concentration levels, using
the peak area ratios of each analyte with comparison to the internal
standard using 1/χ2 as the weighing factor. The acceptable
correlation coefﬁcient (r2) for calibration curves was 0.99 or
higher. The lower limit of quantiﬁcation (LLOQ) was deﬁned as
the concentration of the lowest calibration standard with the
determined signal to noise ratio of least 10:1.
2.5.3. Accuracy and precision
The intra-day and inter-day accuracy and precision of measure-
ment of the target compounds were determined (ﬁve replicates) on
the QC samples on the same day or three sequential days,
respectively. The acceptance criteria for the precision and accuracy
were within 715% (within 720% for LLOQ).
2.5.4. Extraction recovery and matrix effect
The mean extraction recoveries (ﬁve replicates) were measured at
three QC levels for analytes by comparing the peak areas of
analytes from plasma spiked with a reference substance before
sample processing to those of the pretreatment of blank plasma
following by redissolution with standard solution.
The matrix effect was assayed to compare the peak areas of the
analytes from blank blood extracts dissolved with standard
solution to those from the standard solutions directly and
reconstituted in mobile phase at equivalent concentrations.
2.5.5. Stability
Short-term (25 1C for 24 h), long-term (–20 1C for 30 days) and
freeze–thaw (three freeze–thaw cycles) stability of alkaloids and
ginsenosides in the samples were determined with QC samples
(ﬁve samples for each concentration). An acceptable level of
change of actual concentration was set at less than 15%.
2.6. Pharmacokinetic study
Beagle dogs, aged 4–5 years and weighing 1072 kg (certiﬁcate
No. SCXK 2011-0007) were provided by the Experimental
Animal Center of Hunan province. The animal studies were
approved by the Animal Ethics Committee of the Third Xiangya
Hospital of Central South University. All experiments were
conducted in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals.
In our previous study we quantiﬁed the 5 index components in
SFI, the concentrations of BMA, FN, Rg1, Rb1, Rc are 1.7, 0.7,
44.8, 153.0 and 68.9 μg/mL, respectively. In this work, six beagle
dogs (half male and half female) were given 2, 4, or 8 mL/kg of
Shenfu injection pharmacokinetics in dogs 587SFI for single doses trial via a randomized 3 3 crossover design
with a three-week washout period. The dosages in beagles are
calculated by the weight according to the clinical doses in humans
from 20 to 200 mL, so the results can be used to inform the use of
SFI in a clinical setting. The animals were fasted overnight but
with free access to water before dosing. On the day of experiment,
2, 4 or 8 mL/kg of SFI in 5% glucose injection with a total volume
of 100 mL was administered by intravenous drip to dogs in 1 h
with an infusion rate of approximately one drop every 2 s. Serial
blood samples (3 mL) were drawn at 0, 0.33, 0.67, 1 (drip
accomplished), 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72 and 120 h
into plastic whole blood tube with spray-coated K2EDTA. Plasma
samples were obtained following centrifugation at 3500 rpm for
10 min and kept frozen at –20 1C until analysis.2.7. Parameters calculation
The pharmacokinetic analysis of the ﬁve analytes was performed
by a non-compartmental approach using the DAS3.0 software to
calculate area under the concentration–time curve (AUC0–1), half-
life (t1/2) and mean retention time (MRT), etc. The maximumFigure 1 Representative chromatograms of (A) blank plasma;
(B) blank plasma spiked with BMA (20 ng/mL, tR¼1.25 min), FN
(20 ng/mL, tR¼1.25 min) and LA (100 ng/mL, tR¼1.3 min);
(C) plasma sample of 1 h after administration of SFI at a dose of
4 mL/kg.value of concentration (Cmax) and time to reach Cmax (Tmax) were
obtained directly from the experimental process. Statistical ana-
lyses among the three dosages were performed using SPSS 19.0
(Statistical Package for the Social Science). A P value o0.05 was
considered as statistically signiﬁcant for all the tests. All data were
expressed as mean 7 standard deviation (SD).3. Results and discussion
3.1. Optimization of HPLC–MS/MS method
The ion intensities for all compounds were higher in positive
ionization mode than in negative ionization mode. The ion pair
and working parameters for the MRM method are listed in
Table 1. In order to get better resolution and peak shape, methanol,
acetonitrile, water, and 0.1% formic acid were tested as mobile
phases, and methanol with 0.1% formic acid were found to yield
better peak shape, suitable retention time and enhance the
efﬁciency of ionization. The HPLC–MS/MS method is suitable
for both ginsenosides and aconitum alkaloids, which greatly
simpliﬁes the determination. Since ginsenosides and aconitum
alkaloids have different physicochemical properties and are
present in different concentrations in plasma samples, they can'tFigure 2 Representative chromatograms of (A) blank plasma;
(B) blank plasma spiked with Rg1 (1 μg/mL, tR¼2.0 min), Rb1
(5 μg/mL, tR¼4.3 min), Rc (2.5 μg/mL, tR¼4.5 min) and DZP
(diazepam, 0.1 μg/mL, tR¼3.4 min); (C) plasma sample of 1 h after
administration of SFI at a dose of 4 mL/kg.
Yuqiao Zhang et al.588be extracted simultaneously in one preparation while maintaining
good detection and good peak shape. For the preparation process
of plasma samples for ginsenosides determination, we tried
protein precipitation with methanol, liquid–liquid extraction with
water–saturated butanol and ethyl acetate–isopropyl alcohol (1:1,Table 3 Intra-day and inter-day precision and accuracy of BMA, FN
Compound Conc. Intra-day
Mean Accuracy (%)
Alkaloids BMA 0.5 0.54 107.8
(ng/mL) 5 5.23 104.5
40 41.4 103.6
FN 0.5 0.44 87.3
5 5.07 101.4
40 39.80 99.5
Ginsenosides Rg1 0.05 0.045 90.4
(µg/mL) 0.4 0.39 98.8
3.0 2.91 97.0
Rb1 0.25 0.27 106.8
2.0 2.24 112.2
15.0 13.60 90.5
Rc 0.125 0.130 104.0
1.0 1.08 108.3
7.5 6.96 92.7
Table 4 The recovery and matrix effect of BMA, FN, Rg1, Rb1and
Compound Spiked conc.
Alkaloids BMA 0.5
(ng/mL) 5
40
FN 0.5
5
40
LA (IS) 100
Ginsenosides Rg1 0.05
(µg/mL) 0.4
3
Rb1 0.25
2
15
Rc 0.125
1
7.5
DZP (IS) 0.1
aData are mean 7 SD, n ¼ 5.
Table 2 Linear ranges, regression equation, correlation coefﬁcient a
Analyte Regression equation Linear range (n
BMA y¼0.156xþ0.046 0.2–50
FN y¼0.0994xþ0.0579 0.2–50
Rg1 y¼0. 000303xþ0.0000642 20–4,000
Rb1 y¼0. 000203xþ0.00399 100–20,000
Rc y¼0. 000164xþ0.000757 50–10,000
aS/N 410.v/v). The results showed that liquid–liquid extraction with ethyl
acetate–isopropyl alcohol (1:1, v/v) displayed better peak shape,
greater extraction recovery and fewer matrix effects. For aconitum
alkaloids, extraction by organic solvents after alkalifying the
plasma is necessary due to its very low content., Rg1, Rb1 and Rc in dog plasma (n ¼ 5).
Inter-day
RSD (%) Mean Accuracy (%) RSD (%)
6.1 0.51 102.7 4.8
4.2 5.28 105.6 5.1
1.5 41.6 103.9 6.9
2.4 0.47 94.3 7.6
7.5 5.13 102.5 6.2
2.5 40.70 101.8 3.8
3.5 0.050 99.3 10.1
5.4 0.41 102.2 5.1
11.1 2.98 99.3 6.9
7.1 0.26 104.1 5.8
2.3 2.14 106.9 6.6
4.2 14.10 94.0 5.7
1.0 0.130 103.7 7.0
6.4 1.02 102.3 7.6
4.7 7.19 95.9 5.4
Rc in dog plasma.
Recovery (%)a Matrix effect (%)a
85.1711.8 113.0711.5
95.0710.0 85.474.2
92.774.0 85.077.2
79.977.0 106.072.3
77.572.6 92.276.3
81.177.2 83.173.7
99.675.4 95.477.6
86.179.4 106.074.5
78.371.3 102.071.4
87.072.8 103.073.3
80.778.3 95.3713.5
68.874.6 110.077.2
79.374.2 97.774.6
76.976.6 92.874.8
67.175.3 109.077.8
82.375.7 99.475.5
55.374.0 105.073.0
nd LLOQ of ﬁve analytes.
g/mL) Correlation coefﬁcient LLOQ (ng/mL)a
0.999 0.2
0.995 0.2
0.9978 20
0.9995 100
0.9985 50
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3.2.1. Speciﬁcity and selectivity
Representative chromatograms of blank plasma, blank plasma
spiked with BMA, FN, and LA at concentrations of 20, 20 and
100 ng/mL, and a plasma sample taken 1 h after administration of
SFI at a dose of 4 mL/kg are shown in Fig. 1. Similarly,
chromatograms of blank plasma, blank plasma spiked with Rg1,
Rb1, Rc and DZP at a concentration of 1, 5, 2.5 and 0.1 μg/mLTable 5 The stability of BMA, FN, Rg1, Rb1 and Rc in dog plasm
Conc. Room temperature (24 h)
Measured conc.a Accuracy
(RE, %)
Alkaloids
(ng/mL)
BMA 0.5 0.5170.05 102.6
5 5.0070.20 107.4
40 40.771.00 101.8
FN 0.5 0.4870.02 95.6
5 4.9270.40 98.4
40 38.6871.40 96.6
Ginsenosides (μg/mL) Rg1 0.05 0.04970.003 98.4
0.4 0.4170.03 102.5
3 3.0770.20 102.2
Rb1 0.25 0.2470.02 96.0
2 1.9470.09 97.0
15 14.270.80 94.7
Rc 0.125 0.12470.005 99.4
1 1.0170.06 101.4
7.5 7.3270.36 97.6
aData are mean 7 SD, n ¼ 5.
Figure 3 Mean plasma concentration–time curve of ﬁve components in
8 mL/kg) of SFI: A, B, C, D and E represent BMA, FN, Rg1, Rb1 and Rindividually and plasma sample 1 h after administration of SFI at a
dose of 4 mL/kg are shown in Fig. 2. These results show that no
interference by endogenous components, since no interfering
peaks around the retention times of all analytes was observed.
3.2.2. Linearity of calibration curve and LLOQ
The standard calibration curves used for alkaloids and ginseno-
sides in dog plasma all showed good linearity. The results are
shown in Table 2.a.
Storage at 20 1C (30 days) Freeze–thaw cycles
Measured conc.a Accuracy
(RE, %)
Measured conc.a Accuracy
(RE, %)
0.5470.02 107.3 0.5470.01 107.6
4.9370.20 98.7 5.2970.20 105.8
38.4670.80 96.1 42.171.90 105.3
0.5270.05 104.9 0.4870.05 96.4
4.7270.30 94.3 5.2970.30 105.6
36.471.30 91.0 39.871.20 99.5
0.04970.005 97.2 0.04970.002 98.4
0.3970.03 97.5 0.3770.03 92.6
2.8270.20 94.1 2.9270.30 97.4
0.2570.02 101.4 0.2470.02 97.7
2.0270.12 100.9 2.0170.12 100.4
15.8070.70 105.0 16.0470.80 106.9
0.12970.010 102.9 0.12570.010 100.1
0.9970.10 99.4 0.9670.07 96.1
7.6270.48 101.6 7.6070.44 101.6
beagle dogs after intravenous drip of different single dose (2, 4 and
c, respectively (mean7SD, n¼6).
Table 6 Pharmacokinetic parameters of BMA, FN, Rg1, Rb1and Rc in dogs after intravenous drip of different single-dose (2, 4 and 8 mL/kg) of SFI (n ¼ 6).
Parameter BMA (mL/kg) FN (mL/kg)
2 4 8 2 4 8
AUC0–t (μg  h/L) 10.4473.91 27.0976.97 55.19718.19 2.1370.89 6.1771.04 13.4374.44
AUC0–1 (μg  h/L) 10.4473.91 27.5877.47 58.18720.75 2.1370.89 6.1771.04 13.6074.74
Cmax (μg/L) 7.1871.38 17.5876.78 29.7578.45 1.4270.54 3.4871.41 6.1473.30
Tmax (h) 1 1 1 1 1 1
t1/2 (h) 4.1272.63 5.7774.69 5.3374.11 1.5570.48 2.0871.11 2.1570.24
MRT0–t (h) 6.4473.80 8.8374.69 8.4775.94 2.7470.69 3.5071.61 3.6170.35
Vd (L) 18.9175.88 21.65713.65 16.4379.10 19.92713.62 13.9977.12 14.7674.73
CL (L/h) 3.7071.31 2.6570.72 2.7471.31 8.5174.65 4.9470.86 4.7771.47
Parameter Rg1 (mL/kg) Rb1 (mL/kg) Rc (mL/kg)
2 4 8 2 4 8 2 4 8
AUC0–t (mg  h/L) 0.3970.16 0.9670.22 2.1370.94 173.50743.34 303.40791.54 543.50725.51 96.80723.77 155.41742.09 282.27718.11
AUC0–1 (mg  h/L) 0.3970.16 0.9670.22 2.1770.93 249.96789.30 444.467140.88 780.10766.40 154.05752.23 259.48783.03 473.09781.66
Cmax (mg/L) 0.3670.08 0.7570.16 1.5670.57 4.8171.17 8.9073.02 13.8774.12 2.4970.49 4.3871.26 6.8772.02
Tmax (h) 1 1 1 1 1 1 1 1 1
t1/2 (h) 0.3870.09 0.4370.11 0.5370.16 68.11717.80 73.3678.38 70.85711.71 81.91719.15 92.0079.22 93.01724.04
MRT0–t (h) 1.0570.13 1.1270.16 1.2770.24 98.78725.68 106.36712.10 102.74716.89 118.70727.64 133.25713.31 134.72734.68
Vd (L) 3.0870.94 2.4470.42 2.3570.60 1.2570.28 1.5770.44 1.6070.17 1.1070.20 1.5070.34 1.5570.18
CL (L/h) 2.5870.94 1.9470.42 1.8570.60 0.0270.00 0.0270.01 0.0270.00 0.0170.00 0.0170.00 0.0170.00
Data are expressed as mean7SD; AUC0–t, area under the concentration–time curve from 0 to t (t stands for 24, 12, 3, 120 and 120 h to BMA, FN, Rg1, Rb1, Rc, respectively); AUC0–1, area under the
concentration–time curve from 0 h to time inﬁnite; Cmax, the maximum value of concentration; t1/2, elimination half-life; MRT, mean residence time; Vd, volume of distribution; CL, clearance.
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Table 7 Statistics results between doses in single-dose pharmacokinetics trial.
Parameter Compound
BMA FN Rg1 Rb1 Rc
LnAUC0 t/Dose F 1.365 3.565 1.285 1.438 2.857
p 0.285 0.054 0.306 0.268 0.089
LnAUC01/Dose F 1.500 3.556 1.498 0.855 0.945
p 0.255 0.054 0.255 0.445 0.411
LnCmax/Dose F 0.209 0.202 0.060 1.810 2.844
p 0.814 0.819 0.942 0.198 0.090
t1/2 p 0.846 0.115 0.042 0.607 0.135
*Po0.05, a signiﬁcant statistical difference among three dosage.
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For all ﬁve compounds, the intra-day and inter-day precision and
accuracy measured at three concentrations are shown in Table 3.
These results demonstrate that the precision and accuracy values
are well within the 15% acceptance range.
3.2.4. Extraction recovery and matrix effect
The recoveries of all compounds showed no signiﬁcant differences
across the three concentrations (Table 4). Ionization suppression or
enhancement caused by co-eluting compounds originating from
the matrix is also an important problem in HPLC–MS/MS. At the
three QC levels, the observed matrix effects were within the
acceptable limits with the results shown in Table 4.
3.2.5. Stability
No signiﬁcant variability (within715%) of QC concentration was
observed in the short-term stability tests (25 1C for 24 h) and three
freeze–thaw and long-term stability tests (20 1C for 30 days),
indicating that the ﬁve analytes were stable in plasma during the
sample preparation process and storage. The results are shown
in Table 5.
3.3. Pharmacokinetic study
In our study the validated method was applied to the comparative
pharmacokinetic analysis of SFI via intravenous drip administra-
tion. BMA, FN, Rg1, Rb1 and Rc were chosen as the index
components to determine the pharmacokinetics of SFI. The mean
plasma concentration–time proﬁles of the ﬁve analytes after a
single dose administration are illustrated in Fig. 3. The Tmax
equaled the duration of intravenous drip, i.e. 1 h, and the
maximum plasma concentrations were achieved at the point of
drip accomplishment. The pharmacokinetic parameters obtained
from DAS 3.0 based on a non-compartmental model are summar-
ized in Table 6. The pharmacokinetics showed a short t1/2 for the
two aconitum alkaloids, which were approximately 5 and 2 h for
BMA and FN, respectively. In comparison of Rb1 and Rc (Ppd
type ginsenoside with t1/2 of 70 and 90 h, respectively), Rg1 (Ppt
type ginsenoside) had the shortest t1/2 (less than 30 min) which
was in accordance with literature reports11. The results showed
that plasma concentration increased proportionally to the dosages.
By comparing the dose-normalized pharmacokinetic parameters
(AUC0-1/dose, Cmax/dose and t1/2) among the three dosages withSPSS19.0 statistical software, no statistically remarkable differ-
ences were observed (Table 7). The results indicated that all the
ﬁve analytes exhibited linear kinetics over the dosage range of 2–
8 mL/kg after intravenous drip infusion of SFI on beagles.
Due to the light toxicity of BMA and FN, the relative short t1/2
makes them relatively safe in clinical use as they can be eliminated
completely in the dosing interval. For Rb1 and Rc, the longer t1/2
may facilitate maintained effective plasma levels duration dosing
and achieve better therapeutic effect.4. Conclusions
In present study, a rapid, speciﬁc and sensitive HPLC–MS/MS
method was established for the quantitation of BMA, FN, Rg1, Rb1
and Rc in dog plasma samples. We demonstrated the simultaneous
pharmacokinetic evaluation of aconitum alkaloids and ginsenosides
after intravenous drip infusion of Shenfu Injection on beagle dogs.
In conclusion, exposure to the ﬁve components was proportional
over the therapeutic dose range of 2–8 mL/kg used in this study.
Based on these results, a predictable and linear increase in the
systemic exposure of SFI can be expected.Acknowledgments
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